National life science industry leaders and the region’s new companies and research institutions will gather on May 9 for the second annual Delaware’s DNA: 2024 Life Science Conference.
Hosted by the Delaware BioScience Association (Delaware Bio), the full-day event will feature a collection of life science sector executives, investors, new businesses, researchers, and policymakers who will convene for the full-day event at the University of Delaware’s Clayton Hall in Newark. This marks Delaware’s DNA’s return following last year’s successful inaugural life science conference.
This year’s program will include panel discussions and speakers on topics ranging from technologies transforming biomedical research to prospects for a regional precision medicine hub to key life science ecosystem development trends.
The conference will kick off with an in-depth industry assessment from McKinsey Senior Partner Olivier Leclerc. Other panelists and presenters will include IQVIA Chief Digital and Marketing Officer Andrew Ploszay, Aisling Capital Founder Dennis Purcell, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Director Kelvin Lee, Institute for Engineering Driven Health Director Jill Higginson, Maryland Tech Council CEO Kelly Schulz and Kathy Wu of the University of Delaware’s Data Science Institute.
“Last year’s first-ever conference made clear that Delaware’s vibrant life science ecosystem is poised for even greater growth,” said Michael Fleming, president of Delaware Bio. “This year’s Delaware’s DNA will demonstrate the increasing breadth, depth and diversity of Delaware’s growing life science ecosystem and serve as an important annual forum to connect researchers, investors and businesses in new ways that will further build on our momentum.”
In partnership with the Innovation Space, an exciting addition to this year’s conference will be an “Innovation and Investor Showcase” featuring presentations from some of the region’s most innovative, fast-growing companies, including Prelude Therapeutics, Nikang Therapeutics, and Uvax Bio. The showcase will also include reverse pitches from top life science investors, including BioAdvance, Robin Hood Ventures, UD’s University Launch Fund, and The Innovation Space’s First Fund.
“We’re excited to partner with Delaware Bio on this year’s Delaware’s DNA: Life Science Conference,” said Innovation Space CEO Bill Provine. “This is an ideal opportunity to collaborate to showcase some of Delaware and the region’s most impressive early-stage life science businesses and make important connections with the investors who are so critical to their success.”
The conference will feature an app with a partnering tool allowing attendees to schedule one-on-one meetings between companies, researchers, investors, and other businesses.
Sponsors include Adesis, ANP Technologies, Advant-Edge Solution of the Middle Atlantic, AstraZeneca, Avantor delivered by VWR, Biotechnology Innovation Organization (BIO), Comprehensive Cell Solutions, Courtyard by Marriott, CRB, Delaware Business Times, Delaware Prosperity Partnership, Delaware Technology Park, Incyte, The Innovation Space, LabWare, McCarter & English, MRA Group, Nemours, NIIMBL, Philadelphia Convention & Visitors Bureau, Prelude Therapeutics, QPS, and Whiting-Turner.
For conference agenda details, information on sponsorship, and to purchase tickets, click here.
